179 related articles for article (PubMed ID: 8993796)
1. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
[TBL] [Abstract][Full Text] [Related]
2. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
5. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
6. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
7. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
8. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
9. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
10. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for early detection of colon cancer.
Srivastava S; Verma M; Henson DE
Clin Cancer Res; 2001 May; 7(5):1118-26. PubMed ID: 11350874
[TBL] [Abstract][Full Text] [Related]
12. Cohorts with familial disposition for colon cancers in chemoprevention trials.
Burt RW
J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
[TBL] [Abstract][Full Text] [Related]
13. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer.
Tao L; Wang W; Kramer PM; Lubet RA; Steele VE; Pereira MA
Mol Carcinog; 2004 Feb; 39(2):79-84. PubMed ID: 14750212
[TBL] [Abstract][Full Text] [Related]
14. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
Lipkin M
J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
[TBL] [Abstract][Full Text] [Related]
15. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
[TBL] [Abstract][Full Text] [Related]
16. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
17. Large bowel adenomas: markers of risk and endpoints.
Baron JA
J Cell Biochem Suppl; 1996; 25():142-8. PubMed ID: 9027611
[TBL] [Abstract][Full Text] [Related]
18. Early development of cancer chemoprevention clinical trials: studies of dietary calcium as a chemopreventive agent for human subjects.
Lipkin M
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S65-70. PubMed ID: 12570337
[TBL] [Abstract][Full Text] [Related]
19. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer.
Telang N; Katdare M
Oncol Rep; 2007 Apr; 17(4):909-14. PubMed ID: 17342335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
